1. Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS). (April 2017) Authors: Navada, S.; Garcia-Manero, G.; Hearn, K.; Odchimar-Reissig, R.; Demakos, E.; Fenaux, P.; Petrone, M.; Zbyszewski, P.; Fruchtman, S.; Silverman, L. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Epigenetic and molecular signatures of cord blood CD34+ cells treated with histone deacetylase inhibitors. Issue 1 (17th June 2015) Authors: Gajzer, D.; Ross, J.; Winder, L.; Navada, S.; Zhang, W.; Silverman, L.; Chaurasia, P. Journal: Vox sanguinis Issue: Volume 110:Issue 1(2016) Page Start: 79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P746: COMBINATION OF RAS/MAPK MODULATOR AND AZACITIDINE AFFECTS HISTONE MARKS AND IMPACTS THE INNATE IMMUNE SIGNALING PATHWAY IN THE MDS-L CELL LINE. (23rd June 2022) Authors: Rai, R.; Patel, F.; Feld, J.; Melana, S.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.; Reddy, E. P.; Horowitz, A.; Silverman, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 641 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Rigosertib in Combination with Azacitidine Modulates Epigenetic Pathways and can Overcome Clinical Resistance to Hypomethylating Agents in Myelodysplastic Syndromes (MDS). (April 2017) Authors: Chaurasia, P.; Isoda, F.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.P.; Reddy, E.P.; Silverman, L.R. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: THE COMBINATION OF A RAS SIGNALING MODULATOR WITH AZACITIDINE IMPROVES HEMATOPOIESIS IN VIVO AND HAS IN VITRO EFFECTS ON METABOLIC/DIFFERENTIATION PATHWAYS AND INNATE IMMUNE SIGNALING. (September 2021) Authors: Rai, R.; Patel, F.; Melana, S.; Feld, J.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.; Reddy, E.P.; Silverman, L. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: T-CELL RECEPTOR SEQUENCING AND T-CELL MONOCLONALITY: A NOVEL BIOMARKER OF RESPONSE TO IVIG IN MDS PATIENTS WITH AUTOIMMUNE CYTOPENIAS. (September 2021) Authors: Feld, J.; Houldsworth, J.; Reddy, A.; Mai, Z.; Hussein, S.; Navada, S.; Silverman, L.; Mehrotra, M. Journal: Leukemia research Issue: Volume 108(2021)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗